Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: NOTES Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tele-video to Improve Daily Activity

NCT06007664
View directory record Official record
Conditions
Physical Inactivity
Interventions
Tele-Video to Improve Daily Activity
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia

NCT01169909
View directory record Official record
Conditions
Pterygium
Interventions
Ranibizumab
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 9, 2026, 2:05 AM EDT
Completed No phase listed Observational

Comparative Study of Polymetric Clips (Hem-o-Lok) Versus Historical Endoscopic Staplers for Laparoscopic Appendectomy

NCT01830387
View directory record Official record
Conditions
Appendicitis
Interventions
Polymetric clips, Endoscopic Staplers
Device · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Trial of YUMI Uterine Manipulator

NCT02923544
View directory record Official record
Conditions
Gynecologic Condition, Scheduled for a Total Laparoscopic or Robotic-assisted Hysterectomy
Interventions
YUMI manipulator
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 9, 2026, 2:05 AM EDT
Terminated Not applicable Interventional

Effect and Utilization of Protected Time Among Interns on Extended Duty-Hour Call Shifts

NCT00983008
View directory record Official record
Conditions
Fatigue, Sleep Deprivation, Depression
Interventions
Protected time and Dedicated time
Behavioral
Lead sponsor
Providence Health & Services
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Sep 9, 2026, 2:05 AM EDT
Recruiting Phase 2 Interventional

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07194980
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
Nemtabrutinib, Lisocabtagene Maraleucel
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Multi-center Long Term Efficacy Trial of the GFX For Reduction of Glabellar Furrowing

NCT00611273
View directory record Official record
Conditions
Glabellar Furrowing
Interventions
GFX
Device
Lead sponsor
Advanced Cosmetic Intervention
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Beverly Hills, California • San Mateo, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02729896
View directory record Official record
Conditions
Lymphoma
Interventions
Atezolizumab [TECENTRIQ], Obinutuzumab, Polatuzumab Vedotin, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Stony Brook, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 9, 2026, 2:05 AM EDT
Recruiting Not applicable Interventional

Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults

NCT05955339
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension
Interventions
NOTES, AUDIO
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Manchester, New Hampshire • Nashville, Tennessee • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 9, 2026, 2:05 AM EDT
Recruiting Phase 3 Interventional

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143
View directory record Official record
Conditions
Non-small Cell Lung Cancer, NSCLC
Interventions
Pembrolizumab, sac-TMT, Carboplatin, Paclitaxel, Nab-paclitaxel
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
851 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
22
States / cities
Little Rock, Arkansas • Burbank, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

NCT00061893
View directory record Official record
Conditions
Sarcoma
Interventions
celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Collection of Patient-Reported Symptoms and Performance Status Via the Internet

NCT00417040
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Leukemia, Multiple Myeloma
Interventions
internet-based intervention, assessment of therapy complications, Questionnaire Administration
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
95
States / cities
Castro Valley, California • Fremont, California • Martinez, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 9, 2026, 2:05 AM EDT
Withdrawn Not applicable Interventional

Mindfulness Intervention and Symptom Variability in Hearing

NCT04281225
View directory record Official record
Conditions
Hearing Loss
Interventions
Attention to Variability (ATV), Placebo
Behavioral · Other
Lead sponsor
Harvard University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Promoting Independence With Compensatory Cognitive Rehabilitation

NCT04820335
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Structured External Memory Aid Treatment (SEMAT)
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
60 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

NCT01276496
View directory record Official record
Conditions
Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Cilengitide, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Sep 9, 2026, 2:05 AM EDT
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
336
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 259 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

NCT03063762
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Atezolizumab, Bevacizumab, RO6874281
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Results available

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

NCT03958656
View directory record Official record
Conditions
Myeloma-Multiple, Myeloma, Plasma-Cell
Interventions
Cyclophosphamide, Fludarabine, Rimiducid, Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 73 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

NCT00329641
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma
Interventions
carboplatin, paclitaxel, sorafenib tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Social Norms, Messengers, and Processing Fluency to Increase Hypertension Medication Adherence

NCT06066541
View directory record Official record
Conditions
Medication Adherence, Hypertension
Interventions
Scorecard, Social norms, Messenger effects, Processing fluency
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years to 79 Years
Enrollment
65,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 9, 2026, 2:05 AM EDT
Not listed No phase listed Observational

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

NCT03627039
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
SGLT2, Metformin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Not applicable Interventional

A Culturally Tailored Scalable Asthma Intervention for Hispanic Children (Asthma Guardian)

NCT05892302
View directory record Official record
Conditions
Asthma in Children
Interventions
Access to Asma Guardian website/app, Delayed Access to Asma Guardian website/app
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
5 Years to 12 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

NCT01196429
View directory record Official record
Conditions
Ovarian Clear Cell Cystadenocarcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Paclitaxel, Temsirolimus
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
121
States / cities
Phoenix, Arizona • Burbank, California • Los Angeles, California + 82 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Telemedicine in Spina Bifida Transition: A Pilot Study

NCT03466996
View directory record Official record
Conditions
Spina Bifida
Interventions
Intervention group, Standard of care group
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
13 Years to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 9, 2026, 2:05 AM EDT